AMD Invests $20 Million in Absci via PIPE to Enhance AI Drug Discovery with AMD GPUs

Jan 8, 2025, 01:19 PM

Advanced Micro Devices Inc. (AMD) has announced a strategic investment of $20 million in Absci Corporation (ABSI), a company focused on AI-driven drug discovery. The investment, structured as a private investment in public equity (PIPE), aims to enhance AMD's presence in the healthcare sector by leveraging its artificial intelligence chips. This collaboration will see Absci deploying AMD's high-performance compute and software solutions to advance the development of next-generation antibody therapeutics. The partnership is part of AMD's broader strategy to expand into life sciences and other industries, positioning its graphics processing units (GPUs) for specialized applications. Absci, based in Washington state, currently utilizes over 470 AI chips, predominantly from Nvidia, but plans to increase its use of AMD's GPUs following this investment.